QualityMetric, an IQVIA Business: Company Profile

Background

Overview

QualityMetric, founded in 1997, is a leading provider of patient-reported outcome (PRO) and clinical outcomes assessment (COA) measurement solutions. In 2023, the company became an IQVIA business, enhancing its ability to offer comprehensive COA licensing and leverage combined innovative technology solutions and scientific expertise. This integration led to the retirement of the QualityMetric brand, with services now accessible through IQVIA's COA Marketplace.

Mission and Vision

QualityMetric's mission is to amplify the patient's voice in clinical research and patient-reported measurement, aiming to provide actionable intelligence in real time. The company's vision is to set the standard for PROs and COAs, delivering scientifically validated assessments that inform healthcare decisions and improve patient outcomes.

Primary Area of Focus

The company specializes in developing and licensing scientifically validated PRO and COA surveys, offering consulting services, and providing eCOA technology solutions. These services are designed to capture, benchmark, and interpret health outcomes data from the patient's perspective, supporting pharmaceutical, medical device, and healthcare organizations in data measurement that aligns with regulatory recommendations.

Industry Significance

QualityMetric is recognized as a leader in the field of PRO and COA measurement solutions, collaborating with top healthcare and life science companies to better understand functional health and well-being. Its assessments are cited in over 48,000 peer-reviewed articles and have been FDA accepted for use in label claims, underscoring the company's significant impact on the healthcare industry.

Key Strategic Focus

Core Objectives

Enhancing Patient-Centered Research: Developing tools and methodologies that prioritize the patient's perspective in clinical research and healthcare decision-making.

Expanding COA Licensing: Providing a comprehensive range of COA offerings through the IQVIA COA Marketplace, facilitating access to over 160 COA instruments.

Integrating Advanced Technology: Leveraging innovative technology solutions to improve data collection, analysis, and reporting processes.

Specific Areas of Specialization

General Health Surveys: Including the SF-36®v2 and SF-12®v2 Health Surveys, widely used to evaluate functional health status.

Disease-Specific Surveys: Tailored assessments designed to measure health outcomes in specific medical conditions.

eCOA Technology Solutions: Providing electronic platforms for real-time, patient-centered data collection and analysis.

Key Technologies Utilized

eCOA Platforms: Advanced data collection, scoring, and reporting portals that are FDA 21 CFR part 11 and HIPAA compliant.

Linguistic Validation Tools: Ensuring cross-cultural adaptation and linguistic equivalence of assessment instruments.

Primary Markets Targeted

Pharmaceutical Companies: Utilizing PRO and COA assessments in clinical trials and post-market surveillance.

Medical Device Manufacturers: Assessing patient-reported outcomes related to device efficacy and safety.

Healthcare Providers: Implementing patient-centered measurement tools to inform clinical decisions and improve care quality.

Financials and Funding

Funding History

QualityMetric has undergone several funding rounds, including debt financing in November 2020, backed by investors such as Morgan Stanley Credit Partners and Asuun.

Total Funds Raised

The company has raised a total of $4 million in funding.

Notable Investors

Vesey Street Capital Partners: A New York-based healthcare services private equity firm.

Optum: A health services innovation company.

Psilos Group: A healthcare venture capital firm.

Bratenahl Capital Partners: A private equity firm.

Utilization of Capital

The capital raised has been utilized to expand the company's technological capabilities, enhance its eCOA platform, and support the integration into IQVIA, thereby broadening its service offerings and market reach.

Pipeline Development

Key Pipeline Candidates

QualityMetric's pipeline includes a diverse range of PRO and COA instruments, with ongoing development to address emerging therapeutic areas and patient populations.

Stages of Development

The company is in the process of integrating its existing assessments into the IQVIA COA Marketplace, aiming to provide a comprehensive suite of tools for healthcare organizations.

Target Conditions

QualityMetric continues to develop assessments targeting a wide array of conditions, including chronic diseases, mental health disorders, and rare diseases, to support comprehensive patient-centered research.

Anticipated Milestones

The full integration into IQVIA is expected to be completed soon, enhancing access to QualityMetric's assessments and expanding their application across various healthcare settings.

Technological Platform and Innovation

Proprietary Technologies

eCOA Platform: A robust data collection, scoring, and reporting portal that is customizable and compliant with regulatory standards.

Linguistic Validation Tools: Ensuring that assessments are culturally and linguistically appropriate for diverse populations.

Significant Scientific Methods

Patient-Centered Measurement: Utilizing scientifically validated surveys to capture health outcomes from the patient's perspective.

Benchmarking and Data Analysis: Providing norm-based comparisons and benchmarking against over 100 conditions to inform healthcare decisions.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, QualityMetric's integration into IQVIA suggests potential advancements in data analysis and interpretation through AI and machine learning technologies.

Leadership Team

Key Executives

John Hart: Chief Financial Officer. Previously served as Chief Financial Officer & Senior Vice President at National Surgical Healthcare, Inc.

John Ware: Founder and CEO.

Leadership Changes

In January 2021, John Hart was appointed as the Chief Financial Officer of QualityMetric.

Competitor Profile

Market Insights and Dynamics

The market for PRO and COA measurement solutions is growing, driven by the increasing emphasis on patient-centered research and the need for standardized health assessments in clinical trials and healthcare settings.

Competitor Analysis

Key competitors include Obvio Health, Premier Research, and Growman Research Group. These companies offer similar services in the PRO and COA measurement space, contributing to a competitive landscape that fosters innovation and quality improvements.

Strategic Collaborations and Partnerships

QualityMetric's integration into IQVIA represents a significant strategic collaboration, enhancing its ability to provide comprehensive COA solutions and access a broader market.

Operational Insights

The company's focus on scientifically validated assessments and advanced technology platforms positions it as a leader in the PRO and COA measurement field, offering distinct competitive advantages in data accuracy, reliability, and regulatory compliance.

Strategic Opportunities and Future Directions

Strategic Roadmap

QualityMetric aims to expand its portfolio of PRO and COA instruments, integrate advanced technologies into its platforms, and strengthen collaborations with healthcare and life sciences organizations to enhance patient-centered research.

Future Business Directions

The company is focusing on broadening its service offerings through the IQVIA COA Marketplace, aiming to provide a comprehensive suite of tools for healthcare organizations.

Opportunities for Expansion

There are opportunities to develop assessments targeting emerging therapeutic areas and patient populations, as well as to integrate AI and machine learning technologies to enhance data analysis and interpretation capabilities.

Positioning for Future Objectives

QualityMetric's commitment to scientific rigor, technological innovation, and strategic partnerships positions it well to achieve its future objectives in advancing patient-centered research and improving health outcomes.